A

Avenue Therapeutics

D
ATXI
USD
-0.03
(-1.3393%)
Market Closed
155.000
Volume
-19.76
EPS
-
Div Yield
0.058965
P/E
3,163,296.76
Market Cap
Today
-1.3393%
1 Week
-8.866%
1 Month
4.739%
6 Months
-46.229%
12 Months
-87.514%
Year To Date
-81.933%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
U
UTHR
5.02
(1.2627%)
USD
X
XLRN
(%)
USD
R
RARE
-1.75
(-3.3531%)
USD
M
MGNX
0.29
(6.9544%)
USD
G
GLYC
0.0444
(11.84%)
USD
A
AGIO
3.39
(6.5698%)
USD
I
INCY
2.2
(2.7445%)
USD
K
KPTI
0.0008
(0.0909%)
USD
A
ARWR
0.055
(0.2579%)
USD
S
SRPT
-7.62
(-5.9531%)
USD

Title:
Avenue Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
Do you need help or have a question?
Contact Us